Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 7
2013 7
2014 3
2015 1
2016 5
2017 2
2018 4
2019 5
2020 5
2021 12
2022 11
2023 11
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B.
Montali I, Ceccatelli Berti C, Morselli M, Acerbi G, Barili V, Pedrazzi G, Montanini B, Boni C, Alfieri A, Pesci M, Loglio A, Degasperi E, Borghi M, Perbellini R, Penna A, Laccabue D, Rossi M, Vecchi A, Tiezzi C, Reverberi V, Boarini C, Abbati G, Massari M, Lampertico P, Missale G, Ferrari C, Fisicaro P. Montali I, et al. Among authors: degasperi e. J Hepatol. 2023 Jul;79(1):50-60. doi: 10.1016/j.jhep.2023.02.035. Epub 2023 Mar 7. J Hepatol. 2023. PMID: 36893853 Free article.
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
Anolli MP, Degasperi E, Allweiss L, Sangiovanni A, Maggioni M, Scholtes C, Oberhardt V, Neumann-Haefelin C, Dandri M, Zoulim F, Lampertico P. Anolli MP, et al. Among authors: degasperi e. J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.12.023. Online ahead of print. J Hepatol. 2023. PMID: 36931396
Direct-acting antivirals: the endgame for hepatitis C?
D'Ambrosio R, Degasperi E, Colombo M, Aghemo A. D'Ambrosio R, et al. Among authors: degasperi e. Curr Opin Virol. 2017 Jun;24:31-37. doi: 10.1016/j.coviro.2017.03.017. Epub 2017 Apr 15. Curr Opin Virol. 2017. PMID: 28419938 Review.
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Sapena V, et al. Among authors: degasperi e. Gut. 2022 Mar;71(3):593-604. doi: 10.1136/gutjnl-2020-323663. Epub 2021 Mar 19. Gut. 2022. PMID: 33741640 Free article.
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Scholtes C, Facchetti F, Loglio A, Monico S, Fraquelli M, Costantino A, Ceriotti F, Zoulim F, Lampertico P. Degasperi E, et al. J Hepatol. 2022 Dec;77(6):1525-1531. doi: 10.1016/j.jhep.2022.07.016. Epub 2022 Aug 13. J Hepatol. 2022. PMID: 35973578
Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
Farina E, Loglio A, Tosetti G, Degasperi E, Viganò M, Gentile C, Monico S, Perbellini R, Borghi M, Facchetti F, Uceda Renteria SC, Ceriotti F, Cerini F, Primignani M, Lampertico P. Farina E, et al. Among authors: degasperi e. Aliment Pharmacol Ther. 2023 Jun;57(12):1407-1416. doi: 10.1111/apt.17463. Epub 2023 Mar 28. Aliment Pharmacol Ther. 2023. PMID: 36978230
65 results